Butaclamol
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C25H31NO |
| Molar mass | 361.529 g·mol−1 |
| 3D model (JSmol) | |
| |
Butaclamol (AY-23,028) is a type of antipsychotic which was never marketed.[1] Sold as the hydrochloride salt for use in research, the compound acts as a dopamine receptor antagonist.[2]
Synthesis:[3] Review:[4] Book chapter:[5]
Chemistry
[edit]pKa = 7.15 (uncorrected for ionic strength)[6]
References
[edit]- ^ Buckingham J (1985). Dictionary of organic compounds - Google Books. CRC Press. ISBN 978-0-412-54090-5.
- ^ Hall DA, Strange PG (June 1997). "Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors". British Journal of Pharmacology. 121 (4): 731–6. doi:10.1038/sj.bjp.0701196. PMC 1564749. PMID 9208141.
- ^ Bruderlein, F. T., Humber, L. G., Voith, K. (February 1975). "Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. 1. Syntheses and stereochemical and structural requirements for activity of butaclamol and related compounds". Journal of Medicinal Chemistry. 18 (2): 185–188. doi:10.1021/jm00236a016. PMID 1168258.
- ^ Castañer, J., Chatterjee, S. S. (1976). "Butaclamol". Drugs of the Future. 1 (4): 171. doi:10.1358/dof.1976.001.04.64761.
- ^ Chronicles of Drug Discovery, Volume 1, Edited by Jasjit S. Bindra and Daniel Lednicer, page 61, (L. G. Humber).
- ^ Chrzanowski FA, McGrogan BA, Maryanoff BE (March 1985). "The pKa of butaclamol and the mode of butaclamol binding to central dopamine receptors". Journal of Medicinal Chemistry. 28 (3): 399–400. doi:10.1021/jm00381a022. PMID 2579238.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |